Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands

Vaccine

Volumn 26, Issue 46, 2008, Pages 5883-5887

  David, Silke ^a   Vermeer de Bondt, Patricia E ^a   van der Maas, Nicoline A T ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adverse event following immunisation; Pertussis vaccine; Reactogenicity safety; Vaccination programme

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PEDIACEL; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; WHOLE CELL PERTUSSIS VACCINE;

ACCURACY; ARTICLE; COLLAPSE; CONFIDENCE INTERVAL; CRYING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; FEVER; HUMAN; INFANT; NETHERLANDS; PALLOR; PRIORITY JOURNAL; QUESTIONNAIRE; REACTOGENICITY; STATISTICAL ANALYSIS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; CRYING; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; FEMALE; FEVER; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; NETHERLANDS; PALLOR; PARENTS; PERTUSSIS VACCINE; PNEUMOCOCCAL VACCINES; QUESTIONNAIRES; SEIZURES; VACCINES, ACELLULAR; VACCINES, COMBINED;

EID: 53449085895     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.105     Document Type: Article

References (22)

1. Gezondheidsraad. Vaccinatie tegen Kinkhoest. 2004; publicatienr 2004/04:1-117.
2. Vaccinatie van zuigelingen tegen pneumokokkeninfecties. Gezondheidsraad 2005.
3. Vermeer-de Bondt PE, Dzaferagic A, Phaff TAJ, Wesselo C, Maas van der NAT. Adverse Events Following Immunisation under the National Vaccination Programme of The Netherlands, number 11. Reports in 2004. Bilthoven, The Netherlands: National Institute for public Health and the Environment, 2005; 240071002. http://www.rivm.nl/bibliotheek/rapporten/240071002.html.
4. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 (1996) 349-355
5. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350 (1997) 1569-1577
6. Greco D., Salmaso S., Mastrantonio P., Guiliano M., Tozzi A.E., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis Progetto Pertosse Working Group. N Engl J Med 334 (1996) 341-348
7. Tozzi A.E., Ciofi degli Atti M.L., Wassilak S.G., Salmaso S., Panei P., Anemona A., et al. Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines. Vaccine 16 (1998) 320-322
8. Lloyd J.C., Haber P., Mootrey G.T., Braun M.M., Rhodes P.H., and Chen R.T. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. Vaccine 21 (2003) 3746-3750
9. Jefferson T., Rudin M., and DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21 (2003) 2003-2014
10. Knuf M., Habermehl P., Faber J., Bock H.L., Sanger R., Bogaerts H., et al. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 24 (2006) 5627-5636
11. Bonhoeffer J., Heininger U., Kohl K., Chen R.T., Duclos P., Heijbel H., et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 22 (2004) 547-550
12. Bonhoeffer J., Gold M.S., Heijbel H., Vermeer de Bondt P.E., Blumberg D., Braun M., et al. Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 563-568
13. Bonhoeffer J., Vermeer de Bondt P.E., Halperin S., Kempe A., Music S., Shindman J., et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 586-591
14. Vermeer-de Bondt P.E., Dzaferagic A., David S., and Maas van der N.A.T. Performance of the Brighton collaboration case definition for hypotonic-hyporesponsive episode (HHE) on reported collapse reactions following infant vaccinations in the Netherlands. Vaccine 24 (2006) 7066-7070
15. Veen van der Y., Weerd van der M., Maas van der N.A.T., and Vermeer-De Bondt P.E. Toename van bijwerkingen van vaccinaties in 2004. Tijdschr Voor Jeugdgezondheidszorg 39 (2007) 22-27
16. Maas van der NAT, David S, Kemmeren JM, Vermeer-de Bondt PE. Veiligheidsbewaking van het Rijksvaccinatieprogramma; minder bijwerkingen van DKTP-Hib-combinatievaccin sinds de overgang in 2005 naar vaccin met acellulaire kinkhoestcomponent NTVG; 2007; 151:2732-37.
17. Tichmann-Schumann I., Soemantri P., Behre U., Disselhoff J., Mahler H., Maechler G., et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 24 (2005) 70-77
18. Schmitt H.J., Faber J., Lorenz I., Schmole-Thoma B., and Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21 (2003) 3653-3662
19. Zepp F., Knuf M., Habermehl P., Mannhardt-Laakmann W., Howe B., and Friedland L.R. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 149 (2006) 603-610
20. Pichichero M.E., Bernstein H., Blatter M.M., Schuerman L., Cheuvart B., and Holmes S.J. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr 151 (2007) 43-49 49.e1-2
21. Maas van der NAT, Wesselo C, Phaff TAJ, Vermeer-de Bondt PE. Adverse Events Following Immunisation under the National Vaccination Programme of The Netherlands, number 13. Reports in 2006. Bilthoven, The Netherlands: National Institute for public Health and the Environment, 2007; 240071004. http://www.rivm.nl/bibliotheek/rapporten/240071004.html.
22. Vermeer-de Bondt P.E., and Maas van der N.A.T. The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination. Pediatr Infect Dis J 27 (2008) 355-357